Eupraxia Pharmaceuticals Inc.
EPRX
$3.10
-$0.17-5.20%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.92M | 9.76M | 9.40M | 8.74M | 7.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.00M | 31.50M | 31.85M | 31.00M | 27.85M |
| Operating Income | -27.00M | -31.50M | -31.85M | -31.00M | -27.85M |
| Income Before Tax | -25.74M | -28.78M | -27.69M | -31.13M | -28.93M |
| Income Tax Expenses | 1.80K | 36.40K | 36.40K | 41.40K | 36.40K |
| Earnings from Continuing Operations | -25.74 | -28.82 | -27.72 | -31.17 | -28.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 242.00K | 599.00K | 725.70K | 798.40K | 745.20K |
| Net Income | -25.50M | -28.22M | -27.00M | -30.37M | -28.22M |
| EBIT | -27.00M | -31.50M | -31.85M | -31.00M | -27.85M |
| EBITDA | -34.27M | -31.40M | -31.76M | -30.89M | -27.73M |
| EPS Basic | -0.98 | -0.92 | -0.94 | -1.20 | -1.17 |
| Normalized Basic EPS | -0.47 | -0.57 | -0.58 | -0.73 | -0.72 |
| EPS Diluted | -0.99 | -0.92 | -0.94 | -1.20 | -1.17 |
| Normalized Diluted EPS | -0.47 | -0.57 | -0.58 | -0.73 | -0.72 |
| Average Basic Shares Outstanding | 135.70M | 127.36M | 117.27M | 103.65M | 96.54M |
| Average Diluted Shares Outstanding | 135.70M | 127.36M | 117.27M | 103.65M | 96.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
